Pancreatic Cancer Research

ResearcherWuhan Union HospitalActive in the last 2 years

Tao Yin

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-1902-6302; OpenAlex author ID A5101458193. Sources: OpenAlex.

Their work

Papers
28 (first author 2, last author 13)
Trials
0
Grants
0
Labs led
1
Collaborators
55
Papers, trials and grants by year

2011: 3 papers · 2012: none · 2013: none · 2014: 3 papers · 2015: 1 paper · 2016: 2 papers · 2017: 2 papers · 2018: none · 2019: 3 papers · 2020: none · 2021: 1 paper · 2022: 3 papers · 2023: 3 papers · 2024: 2 papers · 2025: 2 papers · 2026: 3 papers

Papers 28

  1. Neoadjuvant Early Stereotactic Body Radiation Therapy Followed by Chemoimmunotherapy in Borderline Resectable and Locally Advanced Pancreatic Cancer. Co-author DOI 10.1016/j.adro.2026.102128↗
  2. PRMT1-Mediated Arginine Methylation Redirects SMAD4 Signaling to Promote Metastasis in Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-26-0923↗
  3. Matrix stiffness induces Ca2+-DCLK1-PIP5K1A mechanotransduction as a context-specific amplifier in pancreatic cancer progression and chemotherapy resistance. Last author DOI 10.1186/s40164-026-00756-6↗
  4. A matrix stiffness gene signature identifies SLC20A1 as a novel mechano-immunological checkpoint enabling synergistic immunotherapy in pancreatic ductal adenoc… Last author DOI 10.1007/s00262-025-04195-w↗
  5. Pancreatic cancer with liver metastasis benefits from chemoradiotherapy compared to chemotherapy alone: a retrospective cohort study from the Surveillance, Epi… Last author DOI 10.21037/tcr-2025-464↗
  6. Single dual-specific anti-PD-L1/TGF-β antibody synergizes with chemotherapy as neoadjuvant treatment for pancreatic ductal adenocarcinoma: a preclinical experi… Last author DOI 10.1097/js9.0000000000001226↗
  7. Single-cell and spatial transcriptomic analyses reveal the cellular origins and drivers of liver metastasis from pancreatic cancer Co-author DOI 10.21203/rs.3.rs-4128922/v1↗
  8. METTL3 promotes pancreatic cancer proliferation and stemness by increasing stability of ID2 mRNA in a m6A-dependent manner. Last author DOI 10.1016/j.canlet.2023.216222↗
  9. Simultaneous Delivery of Dual Inhibitors of DNA Damage Repair Sensitizes Pancreatic Cancer Response to Irreversible Electroporation. Co-author DOI 10.1021/acsnano.3c05009↗
  10. Correction: Combination chemotherapy of valproic acid (VPA) and gemcitabine regulates STAT3/Bmi1 pathway to differentially potentiate the motility of pancreati… Last author DOI 10.1186/s13578-023-01155-8↗
  11. Hyperglycemia Enhances Immunosuppression and Aerobic Glycolysis of Pancreatic Cancer Through Upregulating Bmi1-UPF1-HK2 Pathway. Last author DOI 10.1016/j.jcmgh.2022.07.008↗
  12. A nomogram predicting overall survival for metastatic pancreatic cancer: SEER database analysis Last author DOI 10.21203/rs.3.rs-1410601/v1↗
  13. [The value and controversy of laparoscopic pancreaticoduodenectomy in the treatment of pancreatic cancer]. Co-author DOI 10.3760/cma.j.cn112139-20220410-00154↗
  14. TRIM47 accelerates aerobic glycolysis and tumor progression through regulating ubiquitination of FBP1 in pancreatic cancer. Co-author DOI 10.1016/j.phrs.2021.105429↗
  15. ROS/KRAS/AMPK Signaling Contributes to Gemcitabine-Induced Stem-like Cell Properties in Pancreatic Cancer. Last author DOI 10.1016/j.omto.2019.07.005↗
  16. High glucose promotes pancreatic cancer cells to escape from immune surveillance via AMPK-Bmi1-GATA2-MICA/B pathway. Last author DOI 10.1186/s13046-019-1209-9↗
  17. Combination chemotherapy of valproic acid (VPA) and gemcitabine regulates STAT3/Bmi1 pathway to differentially potentiate the motility of pancreatic cancer cel… Last author DOI 10.1186/s13578-019-0312-0↗
  18. Up-regulation of glycolysis promotes the stemness and EMT phenotypes in gemcitabine-resistant pancreatic cancer cells. Last author DOI 10.1111/jcmm.13126↗
  19. Overexpression of G protein-coupled receptor GPR87 promotes pancreatic cancer aggressiveness and activates NF-κB signaling pathway. Co-author DOI 10.1186/s12943-017-0627-6↗
  20. Gemcitabine treatment promotes pancreatic cancer stemness through the Nox/ROS/NF-κB/STAT3 signaling cascade. Last author DOI 10.1016/j.canlet.2016.08.023↗
  21. Bmi1 inhibition enhances the sensitivity of pancreatic cancer cells to gemcitabine. Co-author DOI 10.18632/oncotarget.9293↗
  22. MiR-652 inhibits acidic microenvironment-induced epithelial-mesenchymal transition of pancreatic cancer cells by targeting ZEB1. Co-author DOI 10.18632/oncotarget.5350↗
  23. Chronic pancreatitis and pancreatic cancer demonstrate active epithelial-mesenchymal transition profile, regulated by miR-217-SIRT1 pathway. Co-author DOI 10.1016/j.canlet.2014.08.007↗
  24. Valproic acid sensitizes pancreatic cancer cells to natural killer cell-mediated lysis by upregulating MICA and MICB via the PI3K/Akt signaling pathway. First author DOI 10.1186/1471-2407-14-370↗
  25. Dendritic cells loaded with pancreatic Cancer Stem Cells (CSCs) lysates induce antitumor immune killing effect in vitro. Co-author DOI 10.1371/journal.pone.0114581↗
  26. Expression of CD44, CD24 and ESA in pancreatic adenocarcinoma cell lines varies with local microenvironment. First author DOI 10.1016/s1499-3872(11)60073-8↗
  27. SIRT1 RNAi knockdown induces apoptosis and senescence, inhibits invasion and enhances chemosensitivity in pancreatic cancer cells. Co-author DOI 10.1038/gt.2011.81↗
  28. Bmi-1 promotes the chemoresistance, invasion and tumorigenesis of pancreatic cancer cells. Co-author DOI 10.1159/000334103↗

Closest collaborators

The 25 strongest of 55 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Heshui Wu · 12 shared papers, 2011–2026 · strength 1.36
  2. Jiaoshun Chen · 5 shared papers, 2022–2026 · strength 1.04
  3. Haoxiang Zhang · 5 shared papers, 2022–2026 · strength 1.04
  4. Chunyou Wang · 13 shared papers, 2011–2023 · strength 0.91
  5. Shihong Wu · 6 shared papers, 2019–2023 · strength 0.82
  6. Zhengle Zhang · 7 shared papers, 2016–2023 · strength 0.72
  7. Shanmiao Gou · 6 shared papers, 2011–2026 · strength 0.71
  8. Hehe Li · 6 shared papers, 2017–2023 · strength 0.70
  9. Long He · 2 shared papers, 2025 · strength 0.69
  10. Qingke Duan · 7 shared papers, 2016–2023 · strength 0.67
  11. Chuanbing Zhao · 2 shared papers, 2025–2026 · strength 0.64
  12. Taoyu Chen · 3 shared papers, 2022–2026 · strength 0.63
  13. Hengqiang Zhao · 5 shared papers, 2016–2019 · strength 0.39
  14. Yao Guo · 2 shared papers, 2021–2024 · strength 0.36
  15. Shuhan Zhao · 1 shared paper, 2026 · strength 0.26
  16. Jun Xue · 1 shared paper, 2026 · strength 0.26
  17. Yingke Zhou · 1 shared paper, 2026 · strength 0.26
  18. Gengdu Qin · 1 shared paper, 2026 · strength 0.26
  19. Yizhou Liu · 1 shared paper, 2026 · strength 0.26
  20. Hongkun Cai · 1 shared paper, 2026 · strength 0.26
  21. Jing Cui · 2 shared papers, 2011–2024 · strength 0.23
  22. Rende Qin · 1 shared paper, 2022 · strength 0.22
  23. Jingyuan Zhao · 1 shared paper, 2024 · strength 0.21
  24. Tao Peng · 1 shared paper, 2024 · strength 0.21
  25. Pengfei Shi · 4 shared papers, 2011–2016 · strength 0.20

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.